Yongjie Xin Selected Research

Yongjie Xin Research Topics

5	Neoplasms (Cancer) 01/2022 - 01/2018
3	Hepatocellular Carcinoma (Hepatoma) 12/2022 - 01/2018
3	Liver Neoplasms (Liver Cancer) 02/2021 - 01/2020
1	Carcinoma (Carcinomatosis) 01/2022
1	Obesity 12/2021
1	Hypoxia (Hypoxemia) 02/2021
1	Stroke (Strokes) 01/2021
1	Ischemic Stroke 01/2021
1	Embolic Stroke 01/2021
1	Infarction (Infarctions) 01/2021
1	Ischemia 01/2021
1	Cholangiocarcinoma 01/2019

2	ChromatinIBA 12/2022 - 01/2022
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
2	MicellesIBA 02/2021 - 01/2018
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Interleukin-27 (Interleukin 27)IBA 12/2021
1	Immunologic Factors (Immunomodulators)IBA 12/2021
1	NanogelsIBA 02/2021
1	Cidofovir (Vistide)FDA Link 02/2021
1	Phosphorylcholine (Phosphocholine)IBA 02/2021
1	polyethylene glycol polyethyleneimine nanogelIBA 02/2021
1	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021
1	Tight Junction ProteinsIBA 01/2021
1	Circulating Tumor DNAIBA 10/2020
1	Biomarkers (Surrogate Marker)IBA 10/2020
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2020
1	MethyltransferasesIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	N-methyladenosineIBA 01/2020
1	MitogensIBA 01/2020
1	Long Noncoding RNAIBA 01/2019
1	Therapeutic UsesIBA 01/2018
1	Sorafenib (BAY 43-9006)FDA Link 01/2018
1	caprolactoneIBA 01/2018